News about "Antibody-Drug Conjugate "

Antengene Corporation receives CDE endorsement to begin pivotal phase 3 CLINCH-3 study of ATG-022

Antengene has received approval from China’s Center for Drug Evaluation to initiate the pivotal Phase 3 CLINCH-3 study of ATG-022, advancing the development of its innovative antibody-drug conjugate for CLDN18.2-positive gastric cancers.

Antibody-Drug Conjugate | 30/05/2026 | By News Bureau

US FDA Approves DECNUPAZ for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

AbbVie has received US FDA approval for DECNUPAZ to treat adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), marking the first and only outpatient-initiated ADC for BPDCN and AbbVie’s first approved Antibody Drug Conjugate (ADC) for hematologic malignancies.

Antibody Drug Conjugate | 30/05/2026 | By News Bureau

Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development

Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.

Antibody Drug Conjugate | 29/05/2026 | By News Bureau

Emiltatug Ledadotin Wins FDA Breakthrough Tag for Adenoid Cystic Carcinoma

Emiltatug Ledadotin receives U.S. Food and Drug Administration Breakthrough Therapy designation for adenoid cystic carcinoma, a potentially innovative and differentiated Antibody Drug Conjugate (ADC) directed against B7-H4, a well-characterised target in certain cancers including ACC.

Antibody Drug Conjugate | 13/05/2026 | By News Bureau

GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom

National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.

Antibody-Drug Conjugate | 21/04/2026 | By News Bureau

GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021

Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.

Antibody-drug Conjugate | 16/04/2026 | By News Bureau |  127

PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan

Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.

Antibody-drug Conjugate | 25/03/2026 | By News Bureau |  225

GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer

Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.

Antibody-Drug Conjugate | 24/03/2026 | By News Bureau |  130

Daiichi Sankyo Submits sNDA in Japan for Datroway in First-Line Metastatic TNBC

Daiichi Sankyo files supplemental application in Japan for Datroway as a first-line treatment for metastatic triple negative breast cancer based on phase III trial data.

Antibody Drug Conjugate | 13/02/2026 | By News Bureau |  174

First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC

The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.

Antibody-Drug Conjugate | 14/01/2026 | By News Bureau |  188